U.S. Building Stock News

NYSE:OGN
NYSE:OGNPharmaceuticals

Assessing Organon (OGN) Valuation After VTAMA Sleep Outcome Data From Phase 3 ADORING Trials

Organon (OGN) is back on investors radar after releasing detailed sub analysis data from its Phase 3 ADORING trials, which showed that VTAMA cream improved sleep outcomes in children with atopic dermatitis and their families. See our latest analysis for Organon. Despite the encouraging VTAMA data, Organon’s recent share price performance has been weak, with a 30 day share price return of negative 18.0% and a 1 year total shareholder return decline of 50.6%, suggesting sentiment remains...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

CoreWeave (CRWV) Quarterly Loss Of US$423m Tests Bullish AI Infrastructure Narrative

CoreWeave (CRWV) FY 2025 results: rapid top line expansion alongside ongoing losses CoreWeave (CRWV) has just posted its FY 2025 numbers, with fourth quarter revenue of US$1.6b and a basic EPS loss of US$0.83, alongside trailing twelve month revenue of US$5.1b and a loss of US$2.68 per share. Over the past six reported quarters, the company has seen revenue move from US$583.9m in Q3 2024 to US$1.6b in Q4 2025. Quarterly basic EPS has ranged from a loss of US$1.82 in Q3 2024 to a loss of...
NasdaqGM:PSNL
NasdaqGM:PSNLLife Sciences

Personalis (PSNL) Losses Of US$81.3 Million Keep Bearish Narratives In Focus

Personalis (PSNL) just posted its FY 2025 figures with Q4 revenue of about US$17.3 million and a basic EPS loss of roughly US$0.26, alongside a trailing twelve month EPS loss of about US$0.91 on revenue of roughly US$69.6 million. Over recent quarters, the company has seen quarterly revenue move between about US$14.5 million and US$20.6 million, while quarterly basic EPS losses have ranged from roughly US$0.18 to US$0.26. This keeps the focus squarely on when scale can start to ease those...
NYSE:VIA
NYSE:VIASoftware

Via Transportation (VIA) Q4 Loss Narrowing Tests Bearish Profitability Narrative

Via Transportation (VIA) FY 2025 earnings recap Via Transportation (VIA) just closed out FY 2025 with Q4 revenue of US$118.9 million and a basic EPS loss of US$0.28, while trailing twelve month revenue reached US$434.3 million against a full year EPS loss of US$1.21. The company has seen quarterly revenue move from US$83.3 million in Q3 2024 to US$118.9 million in Q4 2025, as basic EPS ranged between a loss of US$1.70 and US$0.28 over the same stretch, and over the last year management...
NasdaqGS:PBYI
NasdaqGS:PBYIBiotechs

Puma Biotechnology (PBYI) Margin Resilience Tests Bearish Earnings Forecasts In FY 2025 Results

Puma Biotechnology (PBYI) closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million. Its trailing 12 month revenue came in at US$228.4 million with basic EPS of US$0.62 and net income of US$31.1 million. Over recent periods, the company has seen quarterly revenue range from US$46.0 million to US$80.5 million and basic EPS move between US$0.06 and US$0.98. This gives investors a clear view of how earnings scale with top line...
NYSE:EBS
NYSE:EBSBiotechs

Emergent BioSolutions (EBS) One Off Loss Clouds Return To Profitability Narrative

Emergent BioSolutions (EBS) has just wrapped up FY 2025 with Q4 revenue of US$148.7 million and basic EPS of a US$1.04 loss, capping a year in which quarterly revenue ranged from US$140.9 million to US$231.1 million and EPS swung between a profit of US$1.25 and a loss of US$0.22. Over the trailing 12 months to Q4 2025, the company recorded total revenue of US$742.9 million and basic EPS of US$0.98. This leaves investors to weigh improving headline profitability alongside still uneven...
NasdaqGS:PRAA
NasdaqGS:PRAAConsumer Finance

PRA Group (PRAA) Q4 Profit Of US$1.46 EPS Contrasts With Trailing Loss-Making Trend

PRA Group (PRAA) closed out FY 2025 with Q4 revenue of US$333.4 million and basic EPS of US$1.46, while the trailing 12 month picture shows total revenue of about US$1.2 billion and a basic EPS loss of US$7.79. The company has seen quarterly revenue move from US$293.2 million in Q4 2024 to US$333.4 million in Q4 2025, with basic EPS shifting from US$0.47 to US$1.46 over the same period, alongside a wider loss on a trailing 12 month basis of US$305.1 million. Margins look compressed on the...
NYSE:SWX
NYSE:SWXGas Utilities

Is Southwest Gas Holdings (SWX) Pricing Reflecting Recent Utility Sector Policy Focus?

If you are wondering whether Southwest Gas Holdings at around US$88 per share offers good value today, you are not alone; many investors are trying to work out what a fair price looks like. The stock has returned 0.7% over the last week, 7.6% over the past month, 10.0% year to date, 21.3% over one year, 62.5% over three years and 51.5% over five years, which naturally raises questions about how its current price lines up with its fundamentals. Recent news flow around regulated utilities, gas...
NYSE:UNFI
NYSE:UNFIConsumer Retailing

United Natural Foods Showcases Private Labels And Health Trends For Growth

United Natural Foods (NYSE:UNFI) hosted its 2026 Spring and Summer Selling Show, bringing together thousands of retailers and suppliers. The company unveiled nearly 50 new private label products across categories at the event. Key themes included healthier food offerings, private brand development, and growing interest in gut health. For you as an investor, this matters because UNFI sits at the center of the natural, specialty, and conventional grocery supply chain, connecting brands with...
NYSE:FCN
NYSE:FCNProfessional Services

FTI Consulting (FCN) Margin Decline To 7.1% Tests Bullish Earnings Leverage Narrative

FTI Consulting (FCN) has wrapped up FY 2025 with fourth quarter revenue of US$990.7 million and basic EPS of US$1.80, closing out a year where trailing twelve month revenue reached about US$3.8 billion and EPS came in at US$8.33. The company has seen revenue move from US$894.9 million in Q4 2024 to US$990.7 million in Q4 2025, while quarterly EPS shifted from US$1.41 to US$1.80. This may set the stage for investors to focus on how its 7.1% net margin and forecast earnings growth shape the...
NYSE:HWM
NYSE:HWMAerospace & Defense

Howmet Debt Funded CAM Deal Highlights Growth Potential And Valuation Risk

Howmet Aerospace (NYSE:HWM) announced a plan to acquire Consolidated Aerospace Manufacturing (CAM). The company intends to fund the deal using proceeds from a mix of newly announced and completed debt offerings. The transaction is expected to influence Howmet's operations, market positioning, and capital structure once finalized. Howmet Aerospace, a key supplier of engineered components for aerospace and industrial markets, is moving to expand its footprint with the CAM acquisition. For you...
NasdaqCM:SPT
NasdaqCM:SPTSoftware

Sprout Social (SPT) Q4 Loss Of US$0.18 Per Share Tests Profitability Narrative

Sprout Social (SPT) closed out FY 2025 with Q4 revenue of US$120.9 million and a basic EPS loss of US$0.18, while trailing twelve month figures show revenue of US$457.5 million and a basic EPS loss of US$0.73. Over recent quarters the company has seen revenue move from US$102.6 million in Q3 2024 to US$120.9 million in Q4 2025, with quarterly basic EPS losses ranging between US$0.16 and US$0.30, which keeps the focus firmly on how quickly the business can narrow those losses and improve...
NYSE:XYL
NYSE:XYLMachinery

Xylem Approves US$1.5b Buyback As Shares Trade Below Estimates

Xylem (NYSE:XYL) has authorized a new share repurchase program of up to $1.5b. The program allows the company to buy back shares opportunistically over time. The announcement comes with Xylem shares recently trading around $129.56. Xylem, trading on the NYSE under the ticker XYL, is moving ahead with a sizeable $1.5b buyback plan at a share price of about $129.56. Over the past 3 years, the stock has returned 29.3%, and 37.1% over 5 years, which gives context for how management is choosing...
NasdaqGM:WLDN
NasdaqGM:WLDNProfessional Services

Willdan Group (WLDN) Net Margin Improvement Challenges Bearish Profitability Concerns

Willdan Group (WLDN) capped FY 2025 with fourth quarter revenue of US$173.7 million and basic EPS of US$1.28, while trailing twelve month revenue reached US$681.6 million with EPS of US$3.63 as earnings over the last year were reported to have grown 131.8%. Over the past six quarters the company has seen quarterly revenue range from US$144.1 million to US$182.0 million, with basic EPS between US$0.33 and US$1.28. This sets up a story where improving net profit margin to 7.7% from 4% and high...
NYSE:FOUR
NYSE:FOURDiversified Financial

Shift4 Payments (FOUR) Margin Compression To 1.9% TTM Tests Bullish Growth Narratives

Shift4 Payments (FOUR) has wrapped up FY 2025 with Q4 revenue of US$1.2b and basic EPS of US$0.37, alongside net income of US$25m that keeps the spotlight firmly on how efficiently each transaction is translating into profit. The company has seen quarterly revenue move from US$909.2m in Q3 2024 to US$848.3m in Q1 2025 and then up to US$1.2b in Q4 2025, while basic EPS shifted from US$0.78 in Q3 2024 to US$0.24 in Q1 2025 and US$0.37 in the latest quarter, setting the stage for investors to...
NasdaqGS:STRZ
NasdaqGS:STRZEntertainment

Starz Entertainment Q3 Loss Narrowing To US$20.7 Million Tests Persistent Bearish Narratives

Starz Entertainment (STRZ) opened Q3 2026 with revenue of US$322.8 million and a basic EPS loss of US$1.24, with trailing twelve month EPS at a loss of US$16.16 on revenue of US$1.3 billion. Over recent quarters, the company has seen quarterly revenue move from US$346.9 million in Q2 2025 to US$344.5 million in Q3 2025, US$330.6 million in Q4 2025, and then settle around US$320.3 million to US$322.8 million across the first three quarters of 2026, while basic EPS losses shifted between...
NasdaqGM:XENE
NasdaqGM:XENEBiotechs

Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative

Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US$4.36. The company has seen revenue move from US$0 in both halves of 2024 to US$7.5 million in the latest half. Basic EPS losses widened from US$1.36 and US$1.64 in the first and second halves of 2024 to US$1.90 most recently and a trailing twelve month net loss of US$345.91 million, keeping...
NYSE:RDW
NYSE:RDWAerospace & Defense

Is Redwire (RDW) Pricing Reflect Space And Defense Growth After Recent Share Pullback

If you are wondering whether Redwire's share price still reflects its underlying worth, this article will walk through what the current numbers might be telling you about value and risk. The stock last closed at US$9.07, with recent returns ranging from a 13.5% gain over 7 days to a 31.8% decline over 30 days, and a 35.1% decline over the past year, while the 3 year return sits at a very large gain. Recent news around Redwire has focused on its role in the space and defense sectors,...
NYSE:AHR
NYSE:AHRHealth Care REITs

American Healthcare REIT (AHR) FFO Profile Becomes Central Test Of Bullish Growth Narratives

American Healthcare REIT (AHR) has wrapped up FY 2025 with Q4 revenue of US$604.1 million and basic EPS of US$0.06, rounding out a trailing twelve month picture that shows total revenue of about US$2.3 billion and basic EPS of US$0.42. Over the past few quarters the REIT has seen revenue move from US$540.2 million in Q4 2024 to US$604.1 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.20 per share to a profit of US$0.06 per share. This sets up a year where investors will be...
NasdaqGS:GDRX
NasdaqGS:GDRXHealthcare Services

Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts

GoodRx Holdings (GDRX) is back in focus after launching its Employer Direct platform to help companies reduce high-impact brand drug costs, alongside 2025 earnings, fresh 2026 guidance, and a cluster of analyst rating changes. See our latest analysis for GoodRx Holdings. GoodRx’s recent earnings update, 2026 revenue guidance and the Employer Direct launch have been followed by a sharp reset in sentiment, with a 7 day share price return of 24.29% decline and a 1 year total shareholder return...
NYSE:BUR
NYSE:BURDiversified Financial

Burford Capital (NYSE:BUR) Q4 Loss And Margin Compression Test Bullish Growth Narrative

Burford Capital (NYSE:BUR) rounded out FY 2025 with Q4 revenue of US$33.4 million and a basic EPS loss of US$0.17, as quarterly earnings swung back into the red despite a profitable first half. The company has seen quarterly revenue move from US$244.9 million and EPS of US$0.62 in Q3 2024 to US$178.0 million and EPS of US$0.40 in Q2 2025, and then to US$64.7 million with an EPS loss of US$0.09 in Q3 2025 before landing at the latest Q4 figures. This sets up a results season in which investors...
NYSE:TPC
NYSE:TPCConstruction

Tutor Perini (TPC) Profitability Turn Reinforces Bullish Narratives Despite Rich P/E

Tutor Perini’s FY 2025 Earnings Snapshot Tutor Perini (TPC) has wrapped up FY 2025 with fourth quarter revenue of US$1.5 billion and basic EPS of US$0.55, alongside trailing twelve month revenue of US$5.5 billion and EPS of US$1.53 that mark a clear shift from prior losses. The company has seen quarterly revenue move from US$1.1 billion and an EPS loss of US$1.51 in Q4 2024 to US$1.5 billion and EPS of US$0.55 in Q4 2025. Net income moved from a loss of US$79.4 million to a profit of US$28.8...
NasdaqGS:SBAC
NasdaqGS:SBACSpecialized REITs

SBA Communications (SBAC) Earnings Margin Expansion Challenges Cautious Narratives On Profit Sustainability

SBA Communications (SBAC) closed out FY 2025 with Q4 revenue of US$719.6 million and basic EPS of US$3.48, while trailing twelve month revenue came in at about US$2.8 billion with EPS of US$9.83. Over that same trailing period, net income excluding extra items moved from US$749.5 million to US$1.05 billion, and EPS tracked from US$6.96 to US$9.83, providing a view of how the top and bottom lines have been scaling together. For investors, the combination of higher net margin and a steady...
NYSE:THR
NYSE:THRElectrical

Is It Too Late To Consider Thermon Group Holdings (THR) After Its Strong Share Price Run?

If you are wondering whether Thermon Group Holdings is still attractively priced or already reflecting most of its potential, you are in the right place for a valuation-focused look at the stock. The share price, last closing at US$50.78, comes with a mixed return profile, with a 0.5% decline over 7 days, a 16.9% gain over 30 days, 34.9% year to date, 72.1% over 1 year, 84.6% over 3 years and 136.7% over 5 years. Recent price action sits alongside ongoing news flow around Thermon Group...